Compare Bristol-Myers Squibb Co (BMY) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Financial Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Financial Select Sector SPDR Fund trades at $56.36. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Financial Select Sector SPDR Fund pays none, and Financial Select Sector SPDR Fund is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | XLF | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $56.41 |
52-Week Low | $42.60 | $47.80 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
XLF trades at $56.07, up 0.65% with a bullish technical outlook supported by moving averages. The ETF benefits from strong bank earnings expectations and potential Federal Reserve rate hikes. Recent news highlights sector resilience amid geopolitical tensions and AI-driven market shifts.
Outlook remains positive with earnings season as a catalyst, though risks include economic slowdowns and regulatory pressures. Analyst sentiment leans bullish with institutional focus on dividend growth and financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
